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Credible practice of modeling 
and simulation in healthcare: ten rules 
from a multidisciplinary perspective
Ahmet Erdemir1,11 , Lealem Mulugeta2,11 , Joy P. Ku3,11 , Andrew Drach4,11 , Marc Horner5,11 ,  
Tina M. Morrison6,11 , Grace C. Y. Peng7,11 , Rajanikanth Vadigepalli8,11 , William W. Lytton9,11  
and Jerry G. Myers Jr.10,11* 
Abstract 
The complexities of modern biomedicine are rapidly increasing. Thus, modeling and simulation have become increas-
ingly important as a strategy to understand and predict the trajectory of pathophysiology, disease genesis, and 
disease spread in support of clinical and policy decisions. In such cases, inappropriate or ill-placed trust in the model 
and simulation outcomes may result in negative outcomes, and hence illustrate the need to formalize the execution 
and communication of modeling and simulation practices. Although verification and validation have been generally 
accepted as significant components of a model’s credibility, they cannot be assumed to equate to a holistic credible 
practice, which includes activities that can impact comprehension and in-depth examination inherent in the devel-
opment and reuse of the models. For the past several years, the Committee on Credible Practice of Modeling and 
Simulation in Healthcare, an interdisciplinary group seeded from a U.S. interagency initiative, has worked to codify 
best practices. Here, we provide Ten Rules for credible practice of modeling and simulation in healthcare developed 
from a comparative analysis by the Committee’s multidisciplinary membership, followed by a large stakeholder com-
munity survey. These rules establish a unified conceptual framework for modeling and simulation design, implemen-
tation, evaluation, dissemination and usage across the modeling and simulation life-cycle. While biomedical science 
and clinical care domains have somewhat different requirements and expectations for credible practice, our study 
converged on rules that would be useful across a broad swath of model types. In brief, the rules are: (1) Define context 
clearly. (2) Use contextually appropriate data. (3) Evaluate within context. (4) List limitations explicitly. (5) Use version 
control. (6) Document appropriately. (7) Disseminate broadly. (8) Get independent reviews. (9) Test competing imple-
mentations. (10) Conform to standards. Although some of these are common sense guidelines, we have found that 
many are often missed or misconstrued, even by seasoned practitioners. Computational models are already widely 
used in basic science to generate new biomedical knowledge. As they penetrate clinical care and healthcare policy, 
contributing to personalized and precision medicine, clinical safety will require established guidelines for the credible 
practice of modeling and simulation in healthcare.
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Background
Computational modeling and simulation has become 
increasingly popular in biomedical research and 
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ecosystem of biomedical simulation is fragmented 
and workflows among different biomedical disciplines 
exhibit large operational variations. These circumstances 
introduce difficulties in establishing and conveying the 
credibility of computational modeling and simulation 
outcomes. A common operational framework to pro-
vide a practical basis for the assessment of computational 
modeling studies used for scientific and clinical decisions 
is therefore an imperative need.
Computational modeling has been reliably used in 
traditional engineering disciplines to support product 
development and evaluation. The biomedical field, how-
ever, has been slower to adopt these approaches. In his-
torically strong engineering disciplines, one can apply 
mathematical modeling through direct implementation 
of first principles and community-accepted frameworks 
to human-made systems with known system parameters. 
In biomedical fields, we are often tasked with reverse 
engineering comprehensive, and sometimes complex, 
systems made up of disparate elements with only a partial 
understanding of their properties or even their functions. 
The lack of fundamental first-principle approaches con-
tributes to the challenge that medical practitioners face 
in developing confidence in model-supported results. 
Establishing the credibility of biomedical simulations is 
particularly challenging, as biomedical simulations are 
typically and often purposely built to cover particular 
spatial and temporal scales where acquiring direct meas-
ures is difficult, thus impeding our ability to establish 
accuracy by direct comparison. Despite the challeng-
ing nature of the task, establishing model credibility in 
this domain is particularly important given its potential 
for direct application to patient care. Leading govern-
ment, health, academic, and private institutions around 
the world recognize that computational methods exhibit 
tremendous potential to support clinical research and 
decision-making in healthcare [1–5]. The subject of cred-
ibility has been of increasing interest to the modeling and 
simulation community for many years. In modeling and 
simulation literature, including those in healthcare, veri-
fication and validation have been considered the primary 
component of a model’s credibility. Thus, for the most 
part, equating the credibility of the practice to evaluation 
of validity of the model or model outputs. The present 
study takes a comprehensive approach by treating cred-
ibility as a term inclusive of validation but incorporat-
ing many other aspects that critically impacts the overall 
quality of the modeling and simulation practice.
There are a number of industry and government ini-
tiatives focused on establishing credibility in modeling 
[6, 7] as well as supporting the adoption of computa-
tional models as a trusted source of data. Organizations–
including the European-based Avicenna Alliance [2], the 
industry-led Medical Device Innovation Consortium [3], 
the U.S. Food and Drug Administration (FDA) [4], and 
the United States Congress [5]–have specifically advo-
cated for the use of in silico clinical trials, or trials based 
purely on computational methods to advance the devel-
opment and evaluation of new medical devices, drugs, 
and interventions. Cited benefits of the in silico clinical 
trials approach include streamlined “regulatory evalu-
ation of a medicinal product or medical device/medical 
intervention” [2], development of comprehensive “virtual 
patients” representing a continuum of information [3], 
accelerated innovations in clinical evaluations [4], and 
advancement of new devices and drug therapy applica-
tions [5]. With these developments, establishing frame-
works for regulation of computational simulation has 
become a pressing need worldwide, e.g. as noted by the 
European Economic and Social Committee [8].
These suggestions focused on more mature or forward-
looking application scenarios and did not propose guide-
lines for incorporating credible modeling and simulation 
practices into fundamental and translational research 
initiatives, such as those funded through the Intera-
gency Modeling and Analysis Group since 2004 [9]. The 
community of funded researchers from these initiatives 
formed the Multiscale Modeling Consortium to promote 
the advancement of methodologies to address mecha-
nistic multiscale modeling in biomedical, biological 
and behavioral systems. However, both the Interagency 
Modeling and Analysis Group and Multiscale Modeling 
Consortium encountered substantial skepticism from 
the clinical community on the trustworthiness of such 
models to inform healthcare practice. This initiated a 
multi-year discussion among the community to establish 
methods and guidelines for assessing model robustness, 
with an emphasis on verification, validation and uncer-
tainty quantification [10–12]. Meanwhile, the National 
Research Council and the United States President’s 
Council of Advisors on Science and Technology outlined 
that healthcare benefits of advanced approaches, includ-
ing computational modeling, often accrue once they are 
deemed sufficiently trustworthy both by researchers and 
caregivers [13, 14]. Drawing insights from NASA’s history 
on applying computational models for novel biomedi-
cal applications, the Interagency Modeling and Analysis 
Group/Multiscale Modeling Consortium community 
recognized that developing confidence in models and 
simulations required a holistic process that occurs over 
time and involves multiple intertwined activities.
As an example, consider the evaluation of a model to 
generate trust in using the model outputs for decision-
making purposes. A common theme in the model and 
simulation credibility literature is that trust in a model 
depends strongly on the level of testability of the model 
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and simulation [15–19]. Generally, this involves the 
validation, comparison and evaluation of differences in 
performance to an adequate referent, although verifi-
cation [18], uncertainty quantification and sensitivity 
analysis [20] should also play a substantial part in the 
testing paradigm. Clearly testing a model and simula-
tion performance with respect to a quantitative referent 
that is representative of the real-world system would pro-
vide compelling evidence to the credibility of the model 
and simulation [16, 17]. The engineering modeling and 
simulation literature is a useful resource for methods to 
perform validation comparisons and guidance in evalu-
ating validation results [15, 21], including methods for 
evaluating with only subject matter expert opinion and 
for combining comparable validation factors of differing 
strengths. In combination with the model and simula-
tion output, the extent to which the comparator referent 
represents the real-world system and the extent it cov-
ers the context of use of the model directly relates to the 
strength of the validation activity to influence model and 
simulation credibility.
Direct validation is often impossible for healthcare 
applications because it requires a comparator that 
matches the fidelity of the real-world system and its 
environment with respect to the intended application of 
the modeling and simulation products and their associ-
ated influence and consequence on resulting decisions 
and actions, i.e., the modeling and simulation context of 
use [22, 23]. The inability to perform direct validation 
hinders the broader acceptance and reliability of com-
putational modeling in healthcare. However, indirect 
validation can be accomplished utilizing an additional 
comparator, for example an animal disease model. Of 
course, there may be significant differences between this 
comparator and the clinical situation, for example, in 
the environment experienced by animal models as com-
pared to patients. These differences must be identified 
and evaluated in order to establish trust and confidence 
in the computer model within the stated context of use. 
This leads to a secondary challenge of reporting mod-
eling and simulation processes and testing results with 
sufficient breadth and detail to communicate the appli-
cability of the modeling and simulation in a healthcare 
setting. Further, even if direct validation and adequate 
reporting are performed, adoption of a computational 
model for decision-making would also need to consider 
the rigor and reproducibility of the underlying modeling 
and simulation activities. Computational models, with 
multiple levels of complexity and the potential to inform 
clinical and policy decisions, pose implementation chal-
lenges to the user community. The risks associated with 
inappropriate or ill-placed trust in the model outcomes, 
especially in time-critical situations, must be weighed 
appropriately by review and evaluation of available evi-
dence with respect to the intended use of the model and 
the questions being asked of the model and simulation. 
This illustrates the need to formalize the communication 
of modeling and simulation practices consistent with the 
execution of such practices.
The body of evidence the developer provides directly 
influences the ability to communicate aspects of credibil-
ity [16, 24]. Evidence of credibility in healthcare-related 
modeling and simulation should bridge between devel-
opers and decision makers by communicating aspects of 
credibility in a manner that is independent of the deci-
sion maker’s involvement with the underlying develop-
ment. In an ideal development situation, the decision 
maker, by being an integral part of the development pro-
cess, establishes inherent “buy-in” to the design, assump-
tions, testing and evaluation of the model performance. 
However, decision making and user involvement is not 
guaranteed in the healthcare domain, where models 
can be developed and used for a large variety of applica-
tions (clinical decision making, hypothesis generation for 
experiment design, policy, communication) with a spe-
cific stakeholder in mind, i.e., clinicians, but not always 
with that user community’s involvement. In that sense, 
there should be a common practice to capture and com-
municate this critical ancillary evidence the healthcare 
community might expect from research driven model 
development activities. This further infers the need for 
a general, and customizable, framework that is inclusive 
of all activities of modeling and simulation in establish-
ing modeling simulation credibility not only for scientific 
research but also for translation to a clinical environment.
Roadmap to establish guidance on modeling 
and simulation practices
To provide guidance into this complex process, we 
formed the Committee on Credible Practice of Mod-
eling and Simulation in Healthcare (hereafter referred 
to as the Committee) in 2013 (See Fig. 1). Our mission is 
to develop a holistic and broadly applicable approach to 
understand, establish, and describe guidance and stand-
ards that enable the credible and reliable use of biomedi-
cal modeling and simulation in the practice of healthcare 
and translational research. The Committee is a working 
group of the Interagency Modeling and Analysis Group 
and the Multiscale Modeling Consortium [25], which are 
organized by the U.S. National Institutes of Health (NIH) 
in collaboration with academic researchers and multiple 
U.S. government agencies to promote the advancement 
of computational methods in healthcare practice and 
translational research. In launching this initiative, the 
founding Committee members established the following 
Page 4 of 18Erdemir et al. J Transl Med          (2020) 18:369 
definitions as a general consensus of what it means to 
engage in Credible Practice of Modeling and Simulation 
in Healthcare [25]:
• Credible: Dependable, with a desired certainty level 
to guide research or support decision-making within 
a prescribed application domain and intended use; 
establishing reproducibility and accountability.
• Practice: Any activity involving the development, 
solution, interpretation and application of computa-
tional representations of biological, environmental 
and man-made systems and their interaction thereof.
• Modeling: Virtual, in silico, representation of 
system(s) of interest in a usable form in order to pro-
vide descriptive and predictive metrics for timely and 
systematic exploration of said system(s).
• Simulation: Computational solution of models 
that quantify descriptive and predictive metrics of 
system(s) of interest, including related post-process-
ing efforts to calculate these metrics from raw analy-
sis results.
• Healthcare: Any activity involving development, 
maintenance, advancement, or administration of 
medical care, including research, diagnosis, risk 
assessment, prevention, therapy, rehabilitation, sur-
gery, intervention design, and regulation.
This paper presents the results from the Committee’s 
efforts to establish the “Ten Rules for Credible Practice of 
Modeling and Simulation in Healthcare.” The Ten Rules 
were established through continuous engagement and 
discussions within the Committee and with the broader 
biomedical research community since the Committee’s 
inception in 2013 [25]. Using a two phased approach, the 
Committee assessed factors related to the credibility of 
Fig. 1 The research community events leading to the formation of the Committee on Credible Practice of Modeling and Simulation in Healthcare. 
The mission of the Interagency Modeling and Analysis Group and the Multiscale Modeling Consortium [9] is to share novel methodologies to cross 
spatial and temporal scales in biomedical, biological and behavioral systems, by promoting model reproducibility and reuse [26]. To achieve this 
goal, the end user must be first convinced to use each model through evaluating transparent credible practice rules for modeling and simulation, 
carried out by each modeler
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modeling and simulation activities within and between 
implementing disciplines.
In the first phase, the Committee Co-Chairs assembled 
three task teams from the Committee roster and asked 
them each to identify the top ten rules of credible practice 
from an initial set of 26 rules (Table 1). The task teams’ 
organization followed the Committee estimated proxim-
ity to clinical applications of modeling and simulation in 
healthcare: (1) those weighing towards mathematics and 
computation, (2) those who have a vested interest in the 
end-use of modeling and simulation, and (3) those with 
an inclination towards standards, guidance, evaluation 
and regulation (Additional file 2: Table SM-1). Each team 
also consisted of multidisciplinary members with respect 
to scientific and/or clinical background to minimize bias 
towards any particular discipline. This mix of subject 
matter expertise provided a comprehensive and balanced 
input regarding the goals and objectives of the rules to be 
developed. The three teams came up with different prior-
itizations of the rules, highlighting how discipline, appli-
cation purpose, and background can noticeably influence 
perspectives.
The Committee Co-Chairs curated the ranking, elabo-
ration, and consolidation of these rules to establish an 
initial Committee recommendation of the Ten Rules of 
credible practice of modeling and simulation in health-
care [27]. Rules with similar outcomes in terms of their 
role in the assessment of credibility, or those that may 
enhance each other, were grouped into a single con-
solidated rule. Unique perspectives from the teams and 
individuals were also noted because they might reflect a 
discipline-specific or context-specific need to establish 
credible practice of modeling and simulation.
In the second phase, a public survey—with worldwide 
participation and a wide variety of perspectives and 
background in healthcare modeling and simulation—
was conducted from August 15, 2014 to April 15, 2015. 
Participants provided a relative ranking of the common 
modeling and simulation practices, an updated list of 32 
potential rules synthesized during the discussions of the 
three task teams (Additional file 2: Table SM-2), to guide 
the final selection of the ten rules [28, 29]. Additional 
details of the Committee approach and analysis to reach 
the final ten rules can be found elsewhere [25, 27, 28].
Recommendations for credible modeling 
and simulation practices in healthcare
Here we present the synthesis of the Committee’s efforts 
to develop the Ten Rules for credible practice of mode-
ling and simulation in healthcare from the comparative 
analysis of the Committee’s modeling and simulation 
discipline perspective and the stakeholder community 
survey. The Ten Rules for credible practice of modeling 
and simulation presented evolved from ten rules identi-
fied by initial discussions within the Committee and four 
overlapping credibility concepts that were determined 
through an initial evaluation of the public survey [28]. 
Since then, the Committee perspective and the commu-
nity perceptions were consolidated further. The Ten Rules 
have been hardened by their incorporation into funding 
mechanisms [30–34] and continuous discussions with 
the investigators and funding agency representatives [9] 
who use these rules. They represent a robust and holistic 
approach that not only encompasses rigorous verification 
and validation practices but also adoption of activities 
intended to enhance the practice as a whole. They also 
support the communication of important, and potentially 
neglected, evidence of credibility inherent in the develop-
ment process not presented in early work.
These Ten Rules seek to establish a unified conceptual 
framework to design, implement, evaluate, and commu-
nicate the activities, products, and outcomes of the mod-
eling and simulation life-cycle in a fashion that is agnostic 
to the biomedical science and clinical care domain. The 
Table 1 The initial 26 proposed rules of good practice surveyed within the Committee
Use version control Use credible solvers Explicitly list your limitations
Report appropriately Document your code Provide examples of use
Practice what you preach Develop with the end user in mind Attempt validation within context
Follow discipline-specific guidelines Attempt verification within context Attempt uncertainty (error) estimation
Make sure your results are reproducible Define your evaluation metrics in advance Conform to discipline-specific standards
Be a discipline-independent/ specific example Learn from discipline-independent examples Use appropriate data (input, validation, verifica-
tion)
Define the context the model is intended to be 
used for
Perform appropriate level of sensitivity analysis 
within context of use
Use consistent terminology or define your 
terminology
Get it reviewed by independent users/develop-
ers/members
Provide user instructions whenever possible and 
applicable
Use traceable data that can be traced back to the 
origin
Disseminate whenever possible (source code, 
test suite, data, etc.)
Use competition of multiple implementations to 
check and balance each other
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rules, as detailed in the text and summarized in Table 2, 
may appear to be common sense guidelines, but provide 
a unified framework for both new modelers and seasoned 
practitioners. In the healthcare ecosystem, diverse exper-
tise levels in modeling and simulation drives the need to 
facilitate communication on implementation or to under-
standing simulations predictions between stakeholders, 
e.g., between the developer of the models, practition-
ers of the modeling and simulation practice, users of the 
models, and/or users and decision makers of the knowl-
edge generated by the modeling and simulation practice, 
such as clinicians and policy makers. They are also good 
reminders of the breadth of considerations that needs to 
be accounted for during model development and deploy-
ment, as lacking consideration of one or more will likely 
handicap the credibility of a modeling and simulation 
activity. Computational models have widespread util-
ity to generate new biomedical knowledge and are now 
penetrating clinical care and healthcare policy through 
individualized care and regulatory support, respectively. 
As a result, scientific rigor and clinical safety increasingly 
require established credible practices in modeling and 
simulation.
However, we are fully aware these Ten Rules of cred-
ible practice are not static, just as scientific and clini-
cal methods are not static. With the growing use of the 
rules, we have received continuous feedback from the 
research community on ways to improve the communi-
cation and application of the rules. For example, recent 
developments have demonstrated the need to establish a 
rubric customized for the Multiscale Modeling Consor-
tium to help modelers articulate the level of conformance 
necessary to be achieved for each rule [35]. This is 
because the degree to which each rule should be and can 
be applied will vary dramatically depending on the con-
text of use, state of biomedical knowledge and modeling 
methodologies used. Therefore, we have adopted an iter-
ative approach for continuously updating the Ten Rules 
and supporting guidelines (Fig. 2).
Rule 1—define context clearly
Rule 1 impacts the implementation of six other rules, so 
we advocate establishing a clear definition of the mod-
eling and simulation context of use in the earliest phases 
of the planning, development and implementation of the 
modeling and simulation efforts. A well-articulated con-
text of use statement facilitates the ability of researchers 
and developers to use appropriate data (Rule 2), imple-
mentation techniques (Rule 9), and evaluation methods 
(Rules 3 and 8) to plan and develop the modeling and 
simulation activities. It can also help end-users gain quick 
and accurate insight into the utility, scope and limitations 
of the modeling and simulation (Rule 4).
A complete context of use, as graphically represented 
in Fig. 2, defines the following three elements:
• Domain of use: the domain(s) of healthcare that the 
specific version of the modeling and simulation (Rule 
5) under consideration is intended to inform.
• Use capacity: capacity to which the modeling and 
simulation can be used, including metrics that are 
targeted for predictions and the potential conse-
quences of the use.
Table 2 The Committee’s Ten Rules of credible practice of modeling and simulation in healthcare
Rule Description
1. Define context clearly Develop and document the subject, purpose, and intended use(s) of the model or simulation
2. Use contextually appropriate data Employ relevant and traceable information in the development or operation of a model or simulation
3. Evaluate within context Perform verification, validation, uncertainty quantification, and sensitivity analysis of the model or simulation 
with respect to the reality of interest and intended use(s) of the model or simulation
4. List limitations explicitly Provide restrictions, constraints, or qualifications for or on the use of the model or simulation for considera-
tion by the users or customers of a model or simulation
5. Use version control Implement a system to trace the time history of modeling and simulation activities including delineation of 
each contributors’ efforts
6. Document appropriately Maintain up-to-date informative records of all modeling and simulation activities, including simulation 
code, model mark-up, scope and intended use of modeling and simulation activities, as well as users’ and 
developers’ guides
7. Disseminate broadly Share all components of modeling and simulation activities, including simulation software, models, simula-
tion scenarios and results
8. Get independent reviews Have the modeling and simulation activity reviewed by nonpartisan third-party users and developers
9. Test competing implementations Use contrasting modeling and simulation implementation strategies to check the conclusions of different 
strategies against each other
10. Conform to standards Adopt and promote generally applicable and discipline specific operating procedures, guidelines, and regu-
lations accepted as best practices
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• Strength of influence: the importance of the mod-
eling and simulation to draw conclusions or decisions 
within the stated Domain of Use and Use Capacity 
(Rule 4).
As the context of use prescribes clearly defining the 
expected purpose and application of the model and 
simulations, it contributes to the implementation of all 
aspects of the model and simulation life-cycle. In prac-
tice, developers should seek to clearly delineate (1) the 
descriptions of the real-world system being modeled, (2) 
the level of agreement a model would need to provide to 
influence decisions, (3) the concepts behind the model 
and its use in simulations, and 4) key processes that 
must be captured for the model to be representative of 
the real-world system and its interactions with the mod-
eled environment. An example of how one might practice 
Rule 1 is provided in the work of Pennline and Mulugeta 
[17] and their related activities, which are summarized 
in the Additional file  1: Example 1. For their modeling 
and simulation practice, they define the Domain of Use, 
Use Capacity and intended Strength of Influence of their 
bone physiology computational model. Further guidance 
on describing the context of use can be obtained from 
practical applications documents published in aerospace 
disciplines [36].
Rule 2—use contextually appropriate data
Comprehensively conforming to Rule 2 means that (1) all 
the data used in the development, operation, and evalu-
ation of the modeling and simulation are traceable to 
their original source, (2) the data’s relevance to the stated 
context of use is well articulated, and (3) ideally, the 
Domain of Use experts that are not modeling and simu-
lation practitioners can understand which and how the 
data were used. This rule is closely linked to other rules 
to clearly define the model context (Rule 1), evaluate the 
modeling and simulation within context (Rule 3), and 
explicitly account for the modeling and simulation limita-
tions (Rule 4). Development and operation of a modeling 
Fig. 2 Process for maintaining and evolving the Ten Rules for credible practice in model and simulations in healthcare at the time of the 
development of this manuscript. The Committee utilizes an iterative process to ensure the Ten Rules and its supporting materials remain relevant 
and useful. Government agencies have incorporated the Ten Rules into their funding solicitations to guide applicants on how to develop a credible 
practice plan [30–34]. Informal mechanisms (gray arrows), such as discussions with the funded investigators and program directors of these 
solicitations, provide invaluable feedback to incorporate into the Committee’s guidelines. Within the Interagency Modeling and Analysis group, 
funded investigators also submit semi-annual reports, which include updates on how their projects fulfill the Ten Rules (now available as a online 
form that can be continuously updated on the Interagency Modeling and Analysis Group wiki site [9]). Through this formal process (blue arrows), 
the Committee receives additional feedback for improving the Ten Rules and guidelines
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and simulation with a well-specified context of use (Rule 
1) needs to employ data with established relevance to the 
context of use. Ideally, the scope, type, size, breadth, and 
other characteristics of the data should be aimed towards 
maximizing the Use Capacity (i.e., generalizability) and 
Strength of Influence on the Domain of Use (Fig. 3). To 
achieve these aims, the data may be taken from a wide 
range of sources, including different animal models, 
experimental testing and human cases. An increasingly 
important modeling and simulation data consideration is 
the recognition of sex as a significant biological variable 
that should be more frequently incorporated in study 
design, analysis, and data collection [37]. Furthermore, 
modeling and simulation efforts aimed at personalized 
and precision medicine necessitate the collection and use 
of individual data to formulate and parameterize patient-
specific models.
In addition to the use of relevant data, Rule 2 calls 
for the employment of traceable information in the 
development and operation of modeling and simula-
tion, which is in line with FAIR principles for scientific 
data management (Findable, Accessible, Interoperable, 
Reusable) [38]. Note that in some cases, while the data 
employed are traceable, there may be limited or no avail-
ability for independent third-party evaluation or for 
testing competing implementations (Rules 8 and 9, 
respectively), e.g., when using proprietary data in thera-
peutic development. In these cases, credible practice of 
modeling and simulation may be achieved via evalua-
tion by the appropriate regulatory bodies governing the 
domain of use, for example, the FDA in the case of drug 
development. The availability and use of the appropri-
ate data for modeling and simulation development has 
a direct bearing on the ability to test competing imple-
mentations (Rule 9). For example, different implementa-
tions of the modeling and simulation may place divergent 
requirements on the data, such as on cellular versus 
molecular resolution or the number of time points. An 
example of contextual relevance of data used for model 
development and its evaluation can be seen in the work 
by Rajagopal et al. [39] (also see Additional file 1: Exam-
ple 2). With the goal of predicting musculoskeletal load 
sharing during normal gait of healthy young adult indi-
viduals, they rely on cadaver anatomical data augmented 
with data from young human subjects for model devel-
opment. They track gait data of a young adult subject to 
predict muscular activation and evaluate against muscle 
electromyography patterns.
An important consideration for healthcare modeling 
and simulation activities related to Rule 2 is the qual-
ity of the referent data used to evaluate the model. For 
biological structures and in clinical domains, data can be 
noisy, highly variable, and/or incomplete, indicating chal-
lenges in terms of their acceptance as referent. Assess-
ment of data’s suitability for this purpose, is an important 
consideration that builds upon Rule 2 and impacts any 
activity related to validation. Guidance available in other 
domains, such as [36], can be helpful in this regard.
Rule 3—evaluate within context
The continuous evaluation of modeling and simulation 
within different contexts of healthcare is necessary for 
these tools to become widely accepted. This process is 
one we have observed in the automotive, aerospace, and 
nuclear industries, and emerges as an important step 
when informing high stakes decisions using modeling 
and simulation, e.g., those decisions related to direct-
ing patient care or public policy. Ideally, evaluation of 
any modeling and simulation should be ingrained into 
the iterative development and testing process, accompa-
nied by evidence of efficacy in their respective contex-
tual domains, which will drive the eventual acceptance 
Fig. 3 Relation between Model and Simulation Domain of Use, 
Use Capacity and Strength of Influence. Model and Simulation 
developed for a specific Domain of Use will typically have the 
greatest Strength of Influence within a commensurate range of 
Use Capacity. It may, however, be able to provide inference data for 
other Use Capacity areas. For example, an modeling and simulation 
framework specifically intended for translational research (blue 
line) in pharmaceuticals is likely to have the highest Strength of 
Influence in therapeutics development (e.g. new drug development). 
Similarly, a highly vetted epidemiological modeling and simulation 
to analyze the long-term effect(s) of an FDA-approved vaccine on 
public health (red line) is likely to be most credible for informing 
healthcare policy and preventative therapeutics implementation. The 
Strength of Influence of these examples would likely differ should 
the Use Capacity involve applications related to regulatory approval, 
therapeutics development, and hypothesis testing
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of these technologies into the broader society [40–42]. 
Similarly, for society to fully realize the potential of mod-
eling and simulation to positively impact healthcare, it 
is imperative to apply contextually robust evaluation 
methods.
The evaluation process focuses on the practices of veri-
fication, validation, uncertainty quantification, and sensi-
tivity analysis:
• Verification is the process of determining that the 
computational modeling and simulation accurately 
represents the underlying mathematical model and 
its solution [43, 44]. A domain-specific example of 
code and calculation verification requirements would 
be one developed in accordance with ASME V&V10-
2006 [44].
• Validation of the modeling and simulation is the pro-
cess of determining the degree to which the model 
is an accurate representation of the real world from 
the perspective of its context of use [44]. Due to the 
abstraction needed to represent complex biologi-
cal behaviors within modeling and simulation, some 
deviation from the real system performance should 
always be expected. Therefore, the required level of 
accuracy should be considered in view of the useful-
ness of the modeling and simulation as dictated by its 
context of use.
• Uncertainty quantification of the modeling and sim-
ulation is needed to characterize the pertinent vari-
ability in the model and comparator and to quantify 
their effect on the simulation outcomes [44]. These 
uncertainties emerge from data, modeling assump-
tions, numerical solution techniques and how the 
modeling and simulation addresses biological vari-
ability.
• Sensitivity analysis is useful for establishing the 
degree to which the uncertainty in the model 
output(s) can be attributed to different sources of 
uncertainty in the model inputs [45, 46].
Evaluation metrics and test cases that can appropriately 
demonstrate the predictive performance of the modeling 
and simulation within the stated context of use should 
also be implemented and documented (Rule 6). Further-
more, as the modeling and simulation evolves and more 
data becomes available, the modeling and simulation 
should be continuously evaluated with increasing rigor. 
It is important to note that a commensurate increase in 
the evaluation rigor is expected as the expectations of 
Domain of Use, Use Capacity, and Strength of Influence 
of the context of use increase or change.
The challenge in evaluating and testing models and 
simulations, especially with regard to validation, often 
results from implementation- or discipline-specific con-
siderations, such as with detecting overfitting in data-
driven machine learning implementations [47] or in 
the validation of complex aggregate adverse outcome 
pathway models [16]. In the latter case, the approach to 
the model development implies the need for a hierar-
chical validation at each level of complexity, as well as a 
global validation of the model outcomes. Furthermore, 
the impact of validation depends on the model’s cur-
rent and future intended utility, which may range from 
clinical decision-making to hypothesis generation in sup-
port of mental models. As a result, as the modeling and 
simulation evolves (e.g., matures in its life-cycle, alters 
its desired outputs) or more data becomes available, the 
modeling and simulation should be re-evaluated.
The engineering and physical science literature pro-
vides many excellent sources for finding techniques and 
processes associated with verification and validation [48, 
49]. Each of the modeling cases in the additional files 
includes examples of evaluation activities, both qualita-
tive and quantitative. A recent example illustrates the 
importance of including uncertainty quantification and 
sensitivity analysis techniques to increase our grasp of 
the predictive capability of a complex healthcare-oriented 
model system [50]. In this case, the authors applied tra-
ditional single value approaches, as well as independent 
and joint probability distribution Monte Carlo sampling 
to assess uncertainty propagation, via statistical analy-
sis of output metrics; they also calculated Sobol indices 
to assess global sensitivity. As explained by the study 
authors, the lack of proper uncertainty quantification 
and sensitivity analysis limits the clinical application by 
denying the clinician (i.e., the decision maker) the robust-
ness to tailor the tool to individual or intended patient 
populations. In effect, it gives the user of the model and 
simulation tools the decision-support insight that mir-
rors the formatted information familiar to them from a 
clinical trial cohort that addressed the range of variable 
parameters.
Rule 4—list limitations explicitly
Biomedical phenomena can be convoluted at multiple 
scales, involving linkages across spatial and temporal 
scales and measurements made in  vitro and in  vivo in 
multiple species. To be tractable, modeling and simula-
tion in healthcare must therefore make assumptions that 
are application-specific, which limits generalizability. As 
a result, modelers and developers must clearly identify 
the conditions under which their modeling and simula-
tion cannot be relied upon and provide the rationale 
behind their statements. This not only lends credibility to 
the work, but also facilitates reuse by enabling individuals 
to assess whether the modeling and simulation is suitable 
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for an alternate application. In fact, limitations could 
also be thought of as opportunities for future improve-
ment and highlight paths to enhance the modeling and 
simulation.
Clear communications of potential aleatory and epis-
temic uncertainty is achieved by reporting the underlying 
limitations and assumptions of the model and simulation, 
most notably by putting into context the abstraction to 
the real-world system. This involves describing feature 
inclusion and exclusion, design decisions, types of out-
puts, and the relation of those outputs to the permissible 
uses of the model [36]. There can be overlap between this 
rule and other rules, such as defining the context clearly 
(Rule 1) and using appropriate data (Rule 2). Information 
provided under these other rules could be used to infer 
limitations. Rule 4, however, requires an explicit state-
ment of the limitations, which can go beyond the obvious 
scope described by the other rules.
An example is the musculoskeletal model from Raja-
gopal, et  al. [39] (see Additional file  1: Example 2). The 
model was shown to be suitable for simulating normal 
gait based on data from cadaver specimens and young 
healthy subjects (information captured under Rules 1 and 
2). A logical limitation derived from such information is 
that the model is only suitable for simulating the stated 
conditions: normal gait in healthy individuals. Rajagopal 
and colleagues, however, provide an extensive list of limi-
tations that go beyond these conclusions, demonstrating 
the need to explicitly describe the limits of each study. 
For example, they describe limitations in the model’s 
ability to estimate muscle force-generating capacity due 
to model simplifications.
The Rajagopal et  al. [39] example also demonstrates 
how limitations can arise from a variety of sources. 
Exclusion of components in a model (e.g., cellular types, 
anatomy, signaling pathways), model simplifications 
(e.g., modeling a component in 2-D vs. 3-D), choice of 
parameter values (e.g., using data from one animal model 
for another), and other decisions made during develop-
ment will all influence what can and cannot be modeled. 
Computational constraints and the validation protocol 
can introduce additional limitations. To provide a com-
prehensive description of the modeling and simulation 
limitations, it can be helpful to consider different audi-
ences (e.g., limitations that are important to manuscript 
reviewers versus another modeler who wishes to extend 
the modeling and simulation framework) and differ-
ent experimental scenarios (e.g., simulating varying gait 
speeds or pathologic conditions). Consideration of com-
peting model implementations (Rule 9) may also expose 
modeling and simulation assumptions and limitations 
inherent to the numerical approach underlying the pre-
dictions (e.g., the use of forward versus inverse dynamics 
formulations for gait analysis). Taken together, such 
information provides a richer understanding of the mod-
eling and simulation activity and therefore enhances its 
credibility.
Rule 5—use version control
This rule refers to the need for version control for all 
model, software, data, and documentation files. Version 
control is a system for managing different iterations, or 
versions, of an asset or set of assets. Users sometimes 
start by using ad hoc approaches such as simple journal-
ing (e.g., a laboratory diary) or periodic snapshots of the 
work in progress, possibly using filenames that include 
the timestamp to document model development and 
label different versions of models and data. More com-
prehensive approaches extend this functionality to also 
allow for 1) tracking changes between versions, 2) associ-
ating specific modifications to the creator, 3) and includ-
ing annotations/comments/notes with each version. Such 
systems are known to greatly streamline tracking revi-
sions to source code and documentation by automating 
the acquisition of version control information and history 
with higher frequency. Modern version control systems, 
notably Git [51] and Mercurial (hg) [52], are widely used 
examples. They work at the level of a set of files, rather 
than a single file, making it easy to commit (save as a ver-
sion), log (list versions), clone (share), and diff (compare 
changes) for entire projects. Modern version control sys-
tems also facilitate collaboration on a particular project 
by identifying which individual makes a specific change 
and allowing individuals to work in parallel.
It is important to note that while most modelers and 
software developers follow these practices for building 
new models and software tools, it is less common that 
they use the same approach for documentation and simu-
lation runs or to trace data. Having the ability to associate 
the data, documentation, and simulation logs to the spe-
cific version of the model is critical for accurate interpre-
tation, repeatability, reproducibility, and debugging of the 
simulation predictions. This approach captures the his-
tory of the whole modeling and simulation life-cycle and, 
furthermore, it allows for traceability of model param-
eters and constants, thus ensuring complete reproduc-
ibility of the individual simulation runs, even by a third 
party (Rule 8). Depending on the discipline and intended 
context of use, version control may also relate to stand-
ardized practices of software quality assurance such as 
those of the IEEE [53]. For example, Neymotin et al. [54], 
in their modeling and simulation practice (see Additional 
file 1: Example 3), utilized the Mercurial version control 
management tool. They leveraged this not only for their 
modeling and simulation code but also for manuscripts 
and figures. This exemplifies the advantage of versioning 
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through the whole modeling and simulation life-cycle: to 
establish provenance for data and to associate simulation 
outcomes to model versions.
Rule 6—document appropriately
We define “document appropriately” to mean providing 
the range of information needed for others to (1) assess 
the credibility of the modeling and simulation activ-
ity both under the originally intended context as well as 
under new contexts and (2) understand the nuances of 
reproducing and using/reusing the associated code and 
model. Guidance for the comprehensive reporting of 
computational model studies is available in specific disci-
plines and for certain modeling techniques, e.g., for finite 
element analysis studies in biomechanics [55]. Journal 
publications can also provide some critical details about 
modeling and simulation activity, including informa-
tion related to several of the Rules listed here, e.g., define 
context clearly (Rule 1). Due to the format and purpose, 
however, scholarly publications cannot comprehensively 
provide all the necessary information to describe the 
modeling and simulation. If the associated code or model 
is made available, as recommended when disseminat-
ing broadly (Rule 7), comments should be included in 
those files to explain implementation decisions and aid in 
their reuse. Additional documentation, such as a user or 
developer guide (see [56] for an example), can similarly 
provide detailed explanations not suitable for a journal 
publication. Useful information that might be found in 
such guides include best practice workflows for using 
the code or model, guidance on parameter selection, and 
common pitfalls.
The modeling and simulation activities related to work 
by Pennline and Mulugeta [57] illustrate how documen-
tation is a continuous activity throughout the life-cycle of 
the model, and in their case, it directly targets informing 
the stakeholders. Not only were the code and interfaces 
documented, model features and credibility assessment 
have been routinely conveyed through reports, presenta-
tions, and briefings along with scholarly work. All these 
were curated for access by interested parties (see details 
in Additional file 1: Example 1).
Rule 7—disseminate broadly
Traditional scientific dissemination involves publica-
tion with an emphasis on providing a thorough Materi-
als and Methods section that permits others to replicate 
the experiments performed. Studies leveraging modeling 
and simulation generate and utilize many assets, includ-
ing data, workflows, models, simulation software, and 
simulation results (raw and post-processed). “Dissemi-
nate broadly” refers not just to the traditional sharing 
of knowledge via publications, but also to the sharing of 
modeling and simulation assets.
When shared, these assets provide interested par-
ties the opportunity to develop direct outcomes and/or 
by-products of the modeling and simulation. For exam-
ple, data can be used to redevelop a model from scratch; 
workflows can be used to evaluate the completeness and 
reproducibility potential of the modeling and simula-
tion processes; models and simulation software can be 
modified for new analyses with different context of uses; 
simulation results can also serve as a reference for con-
clusions made and support further in-depth analysis by 
a third party. The Methods section of traditional publica-
tion platforms are generally used to point towards data, 
document workflows, and describe the modeling and 
simulation software. Unfortunately, scholarly publication 
is generally not sufficient to embed all the details, and in 
the majority of cases, it is not even practical. Contem-
porary simulation studies and related models are often 
a combination of large pieces of software, sometimes 
instantiated in still larger specialized simulation software 
environments. And source code is now typically too large 
for printed listings. Even models that can be described 
succinctly as sets of equations are still not generally fully 
replicable due to different preferences of developers in 
choosing solver settings, e.g., integrators, randomizers. 
More detailed information on these issues can be found 
in domain-specific discussions of sharing computational 
models and related resources, e.g., in the discipline of 
biomechanics [58].
Examples of extensive sharing of modeling and simu-
lation assets exist. Rajagopal et  al. [39], publicly dis-
seminated their musculoskeletal model, data to drive 
simulations, and documentation at SimTK [59] as part 
of their practice (Additional file 1: Example 2). Similarly, 
Neymotin et al. [54] leveraged a public repository [60] to 
share model code and published in open access journals 
(Additional file 1: Example 3). There may be a desire to 
limit the extent of dissemination. In such cases, sharing of 
models (and related data and documents) with a limited 
number of parties may still provide the benefit of third-
party inspection and evaluation, which can enhance the 
credibility potential of the practice. For example, Penn-
line and Mulugeta [57] made their model available to its 
specific user base, in this case NASA researchers (see 
Additional file  1: Example 1). In other cases, the model 
was made available to reviewers (also the case for the 
study by Verma et  al. [61] in Additional file  1: Example 
4). Such strategies can support commercialization of the 
modeling and simulation practice while accommodating 
activities that have direct relevance to credibility.
We should note that dissemination of simulation 
software both in binary and source code has become a 
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routine strategy in many subdisciplines of the biomedi-
cal research ecosystem. Sharing of models in machine 
and human readable format (in source markups) has also 
gained traction with varying degrees of success, depend-
ing on the biomedical domain [39, 62]. We recommend 
the use of existing repositories for disseminating code 
and models. While shared code and models may be 
placed on a laboratory website, it is preferable to utilize 
an archival location such as GitHub [63], journal web-
sites, or specialized model databases, domain reposito-
ries and or general repositories such as [59, 60, 64–66] 
to ensure long-term availability of the shared assets. It 
would also be valuable to have links from such reposito-
ries to repositories that track related experimental and 
clinical data. To ensure discoverability, digital object 
identifiers should be acquired for the shared assets, 
which has become an available feature in many reposito-
ries, e.g., SimTK, figshare, Zenodo [59, 65, 66]. Ideally, it 
should be possible to reproduce one or more individual 
figures from a journal article using the downloaded code 
or model. As noted under other rules, code and accom-
panying documentation should include metadata relating 
to parameter provenance, simulation scenarios, extensi-
bility and limits.
Rule 8—get independent reviews
Following the other rules described in this article will sig-
nificantly increase the credibility of a modeling and simu-
lation activity. Having non-partisan third-party reviewers 
evaluate the activity will further enhance the communi-
ty’s trust. For this rule, “third-party” reviewers refers to 
end-users or modelers/developers evaluating the activ-
ity in its entirety. Peer reviews of manuscripts, which 
include descriptions of the modeling and simulation 
activity, are discouraged as the sole form of third-party 
review since they provide a limited assessment, poten-
tially only superficially addressing Rules 1–4. Choosing 
who reviews a modeling and simulation activity depends 
on the intended use and should be considered at the out-
set of a modeling and simulation activity.
For many modeling and simulation activities, a natural 
choice for a third-party reviewer would be the intended 
end-user. This might be a clinician, an educator, or a non-
computationally inclined researcher. These individuals 
provide valuable feedback on the usability and relevance 
of the activity for their applications. Examples include 
a cardiologist assessing a model’s suitability for deter-
mining patient-specific pharmacological treatment for 
pulmonary hypertension or a health department policy 
maker evaluating a population model for deciding the 
most effective communication campaign. Specific ques-
tions these end-user reviewers want answered often 
relate to the other Rules:
• Define context clearly (Rule 1) and List limitations 
explicitly (Rule 4): End-user reviewers need sufficient 
information to evaluate whether or not the activity is 
suitable for their research question of interest.
• Use appropriate data (Rule 2) and Evaluate within 
context (Rule 3): End-user reviewers want to exam-
ine the validation evidence to decide the level of trust 
they have in the model output(s).
• Document appropriately (Rule 6): Clearly written 
documentation with sufficient details will enable 
a reviewer to answer questions that can arise when 
reproducing a modeling and simulation study or 
adapting a tool to their application.
• Test competing implementations (Rule 9): The end-
user reviewer may be interested in how results of 
the modeling and simulation activity compares with 
those generated by existing tools or implementations, 
as these provide a previously established reference of 
performance.
• Conform to standards (Rule 10): If a community has 
common formats or methods for any modeling and 
simulation activity, including its evaluation, the end-
user reviewer will be interested in how the modeling 
and simulation activity follows these standards. Con-
forming to such standards facilitates comparisons 
and enhances interactivity with the community’s 
other modeling and simulation activities.
Modelers/developers assess a modeling and simula-
tion activity from a development perspective, want-
ing to extend the modeling and simulation activity for a 
novel use or compare it with other similar activities. So 
their questions necessarily differ from those of end-user 
reviewers, though they can still be categorized into the 
stated Rules. For example, sufficient documentation for 
an end-user reviewer may consist simply of the mechan-
ics of running a model, while a modeler reviewer would 
want details of how the model was constructed, the 
parameters used in running the model, and references for 
extending the simulation code. Additionally, a modeler 
reviewer will often want direct access to the source code, 
models, and underlying data, and thus using version con-
trol (Rule 5) and disseminating broadly (Rule 7) take on 
increased importance for these reviewers.
Strategies to involve peer-reviewers of scholarly publi-
cation to also perform third-party review of model and 
modeling and simulation processes have been tested in 
biomedical disciplines, e.g., for computational biome-
chanics [67]. The musculoskeletal model described by 
Rajagopal et  al. [39] was disseminated during the sub-
mission of their manuscript (also see notes in Additional 
file 1: Example 2). The reviewers performed simulations 
to reproduce reported results. This exercise identified 
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problems with input data that were utilized in the origi-
nal submission and resulted in the acquisition of higher 
quality data by the study authors for the resubmission. 
Incorporating third-party review, not only of publica-
tions but also of models, demonstrated the importance 
of dissemination (Rule 7) to facilitate a comprehensive 
review. While both the reviewers and the practitioners of 
the modeling and simulation workflow noted the added 
burden on the overall review process, they also strongly 
agreed that the quality of modeling and simulation 
increased after such reviews.
One outstanding question is how to identify and 
engage non-partisan reviewers. No best practices have 
been developed in this regard. Recent funding initiatives, 
e.g., from the Interagency Modeling and Analysis Group 
and the Multiscale Modeling Consortium [30], ask grant-
ees proposing computational modeling studies to provide 
plans for addressing and reporting modeling and simula-
tion credibility. Ideas worth exploring include budgeting 
a portion of grant funding to hiring third-party reviewers 
to the activity of establishing collaborations with other 
grantee labs to assess each other’s models. Verma et  al. 
[61] relied on re-implementations by an independent lab-
oratory member who was not involved with the project 
(see Additional file 1: Example 4). The model by Neymo-
tin et  al. [54] was reviewed for run-capability on multi-
ple platforms by a ModelDB [60] curator (see Additional 
file 1: Example 3). Note that the ideal cross-lab validation 
involves groups that are not working or have not previ-
ously worked together. Publishers may provide more 
comprehensive reviews of modeling and simulation stud-
ies in the future as well. The journal PLOS Computational 
Biology recently launched a pilot to provide simulation 
and results verification for authors using the Center for 
Reproducible Biomedical Modeling’s [68] services. Ulti-
mately, which third-party review mechanism is utilized is 
not nearly as critical as having thoughtful, impartial eval-
uations predicated on accepted guidelines/requirements, 
which improve not just the credibility of the modeling 
and simulation activity but also the activity itself.
Rule 9—test competing implementations
Model and simulation development often results from 
the effort to improve an existing model or analysis pro-
cess by incorporating new techniques or knowledge. 
Thus, comparison of a competing model application to 
a prior implementation can provide insight on the evo-
lution of the model strategies and algorithms, as well 
as on the impact of results from which historical con-
clusions have been drawn. For the healthcare model 
practitioner, this comparison provides valuable under-
standing into the model behavior with respect to familiar 
standards of performance. A comprehensive contrast of 
modeling strategies also informs the user about the inter-
play between model algorithms, operational factors, and 
model parameters in supporting decision tools and strat-
egies across a range of application scenarios. Differences 
may also illustrate where future model improvements can 
be made or clarify that decisions should be supported 
by an ensemble of competing model output(s). When 
combined with uncertainty quantification approaches 
in Rule 3, this competitive comparison of modeling 
techniques provides the model practitioner with much 
needed insight for projecting how a model can support 
their specific implementation and may lead to ensemble 
application of competing models to overcome individual 
limitations.
In the case of a unique model development effort, 
where the model developer and practitioner lack compet-
ing implementations, similar insight may be drawn from 
pursuing alternative formulations or numerical imple-
mentations. The conceptual modeling phase of modeling 
and simulation often involves weighing the pros and cons 
of competing approaches, and thus, the decision to use a 
particular approach may provide a valuable understand-
ing of modeling and simulation performance. In practice, 
this may be achieved by implementation on alternative 
platforms or in alternative programming languages that 
may require different orders of operations and can illus-
trate important features of model performance. Report-
ing such implementation tests establishes due diligence 
in the practical application of a model.
The benefits to this credible practice are exemplified 
by successful application in the physical science and 
engineering disciplines, where the use of so-called sur-
rogate models extends testability [36]. These surrogate 
models, notably data-driven models now extending to 
machine learning, provide a continuous comparative 
representation at a focal area of application, usually with-
out consideration of all the original model and simula-
tion underlying limitations. In this case, the intent is to 
enhance the testability of the model in some combined 
parameter space that may not be directly measurable. 
The surrogate models would also need to follow credible 
practice to allow evaluation as viable comparators. In rel-
evance to this rule for healthcare, the modeling and sim-
ulation practitioners may decide to implement different 
simulation strategies or use different models for the same 
purpose. In modeling and simulating musculoskeletal 
movements, Rajagopal et al. [39] decided to use two other 
publicly available and commonly used musculoskeletal 
models, specifically to assess relative computational cost 
(see Additional file 1: Example 2). The implementation of 
different models or different simulation strategies may be 
challenging or burdensome. Hence, efforts analyzed in 
Additional file 1: (Examples 3 and 4; Neymotin et al. and 
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Verma et  al. [54, 61], respectively) did not attempt any 
other implementations. Nonetheless, explicit acknowl-
edgment of the lack of such attempts can provide the 
audience a roadmap for the development of alternative 
strategies.
The burden of testing and comparing competing imple-
mentations need not fall on a single group, however. 
Competing implementations by different modeling and 
simulation teams can be curated through “grand chal-
lenge competitions”, e.g., similar to the one conducted for 
the prediction of in vivo knee joint loading [69]. Organic 
collaborations among teams with synergistic interest in a 
specific modeling goal can also serve as a framework for 
comparing modeling and simulation for the same context 
of use but with different flavors of implementation [70].
Rule 10—conform to standards
Just as in the case of designing, implementing and report-
ing rigorous and repeatable experimental protocols, user 
communities expect model development and utilization 
to conform to applicable, and sometimes discipline-spe-
cific, development guidelines, operating procedures, and 
standards. Paraphrasing the International Organization 
for Standardization [71], standards, when consistently 
applied, represent a means of providing requirements, 
specifications, and guidelines that establish that the 
modeling and simulation materials and products fit 
the intended purpose (e.g., modeling and simulation is 
appropriate for the context of use). The collection of rel-
evant standards represents a minimum set of guidelines 
consolidating the applicable community expectations. 
Failing to follow and report outcomes associated with 
applicable community guidelines reduces confidence in 
the modeling and simulation and increases the difficulty 
of communicating credibility. In contrast, following per-
tinent standards and practices conforms with expecta-
tions and therefore promotes acceptance and utilization.
The decision of which standards (coordinated or de 
facto) to follow depends on the discipline, the institu-
tion leading the development, as well as the standards 
expected by the user community and any governmental 
or private regulating bodies. The importance of specific 
standards will vary with the development stage of the 
modeling and simulation application. The Ten Rules can 
provide an overarching framework for considering which 
standards to incorporate into a modeling and simulation 
project. One might expect to follow standards from insti-
tutional review boards for data acquisition and/or the use 
of animal and human subjects (Rule 2), standards and 
guidelines related to verification, validation, and uncer-
tainty quantification [25, 43, 44, 53, 72–74] (Rule 3), and/
or community-accepted best practices for dissemina-
tion, such as using common markup languages [75] (Rule 
7). Many institutions require reporting modeling and 
simulation products by following in-house or discipline-
specific minimum reporting standards (Rule 6) [55]. We 
encourage adherence to standards which promote trans-
parency, i.e., open-source technology, to improve insight 
into and adoption of modeling and simulation whenever 
possible. The Internet protocols is an example of such 
open standards. More information about open standards 
is available at [76].
A few examples of adopting well-defined standards 
or de facto best practices (for overall workflows, model 
representation, or individual processes) are worth not-
ing. The whole workflow of Pennline and Mulugeta [57] 
(see Additional file 1: Example 1) was faithful to NASA-
STD-7009, a technical standard that establishes uniform 
modeling and simulation practices related to NASA’s 
mission [6]. Verification and validation efforts of Raja-
gopal et al. [39] (see Additional file 1: Example 2) hinged 
on guidance on best practices applicable to musculo-
skeletal modeling [72]. Similarly, modeling by Neymotin 
et al. [54] (see Additional file 1: Example 3) relied on best 
practices encouraged in training sessions of NEURON 
[77], with model dissemination conforming to the stand-
ards of ModelDB [60]. Both of these are geared towards 
simulation of neurons. Verma et al. [61] represented their 
model in Systems Biology Markup Language [78] (see 
Additional file  1: Example 4), an open standard for the 
exchange of computational models in system biology.
Clearly, the application of appropriate standards chal-
lenges the developer to identify and follow these stand-
ards early in the development cycle. This is especially 
true as modeling and simulation in healthcare increas-
ingly requires a multidisciplinary approach to address 
modeling challenges to engage in higher stakes ques-
tions. Clear and on-going developer-user communica-
tion is needed to effectively combine multidisciplinary 
standard formats, methods of evaluation, and devel-
opment requirements. The benefits of aligning a mod-
eling and simulation activity with existing standards are 
worthwhile, improving community perception of the 
model application and fostering a deeper understanding 
of the development rigor of the modeling and simulation 
product.
Conclusions: scope and utility of rules for credible 
practice of modeling and simulation
The biomedical sciences and clinical disciplines are 
diverse and multidisciplinary, and the modeling and sim-
ulation community is highly heterogeneous from domain 
experts to novice enthusiasts. Intentions of modeling and 
simulation vary dramatically as well, ranging from medi-
cal training to hypothesis generation to clinical decision-
making. The perception and relative importance of the 
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Ten Rules described here and the intensity at which they 
are applied are expected to be influenced by multidisci-
plinary, organizational, and contextual factors. The con-
tribution of this study hinges on treating credibility as a 
term inclusive of validation but incorporating many other 
aspects that critically impact the overall quality of the 
modeling and simulation practice. Such a comprehensive 
treatment is rare in literature, nonetheless exists as a sign 
towards the need for such guidance, e.g. Law, Rabeau, 
Behrend, and Bodner et  al. [19–21, 24]. We accomplish 
this by establishing a set of expected activities and infor-
mation that is sufficient to establish credibility for the 
user/decision maker’s unique use case, understanding 
that available models will be used by both intended and 
unforeseen users. The rules are intended to be applicable 
throughout the entire model life-cycle, which can include 
stages for ideation, development, calibration, bench-
marking, accreditation, use as originally intended, and 
reuse. The rules are not limited solely to model develop-
ment and testability. A majority of activities in relation to 
the Ten Rules span the whole modeling and simulation 
life-cycle. A few focus on certain stages, i.e., evaluation 
activities primarily belong to benchmarking. A more 
detailed correspondence between the Ten Rules and 
modeling and simulation life-cycle stages is provided as 
(Additional file 2: Table SM-3). The relationship between 
the rules and modeling stages demonstrates the compre-
hensiveness of the Ten Rules that extend beyond singular 
activities.
As a tightly linked cohort, they represent a customiz-
able framework to tailor to the domain of application, 
state of development, and stakeholders. Therefore, these 
rules serve as a reference to guide the everyday practice 
and communication of modeling and simulation cred-
ibility for developers, researchers, and healthcare stake-
holders in the utilization of modeling and simulation 
products. Followed in their entirety, these Ten Rules 
support the execution and communication of activities 
that realize the metascience themes of reproducibility, 
comprehensibility, and transparency. They also reinforce 
the acceptance of a modeling and simulation credible 
practice whose foundation is premised on validation and 
other testable measures.
To enhance the practitioners’ understanding of the 
potential virtues of the Ten Rules credible practice, a 
comprehensive perspective on the benefits of including 
and the pitfalls of excluding activities related to each rule 
can be found in the Additional file 2: Table SM-4. When 
following these practices to enhance the communica-
tion of model and simulation credibility, we recommend 
that the practitioner state if a rule is implemented or not. 
If it is implemented, descriptions of the implementa-
tion describing how and the degree of compliance with 
the rule relative to the model’s context of use should be 
provided. Similarly, if a rule is not implemented, details 
explaining the decision describing why should be given. 
The implications of not addressing individual rules 
should indicate the potential impacts on the ability to 
support scientific or clinical decision and policy develop-
ment, all in relevance to the model’s context of use. An 
example of this would be that an inability to complete 
Rule 8 (Get Independent Reviews). One impact could be 
the lack of independent affirmation of the influence of 
the assumptions of limitations, thus influencing model 
and simulation interpretation, given in Rule 4. By giving 
the user such transparent and comprehensive insight into 
the model and simulation’s development life-cycle, the 
modeler enables the user community to critically evalu-
ate the level of confidence in the model’s intended use 
and the feasibility of the model’s application in future 
implementations.
It is highly likely that holistic practices for credible 
modeling and simulation will be equally applicable to 
emerging data-driven computational strategies for scien-
tific discovery and clinical care, such as big data analyt-
ics and machine learning. In order to conform to these 
rules, we anticipate the development of tools as well as 
infrastructure to customize or automate potentially bur-
densome activities. We also expect and have already 
observed the expansion and evolution of these rules as 
well as their application, as achieving a good represen-
tation of credibility is a continuous process. As such, 
we have adopted an ad hoc, but iterative process for 
updating the rules and supporting guidelines based on 
the feedback we receive from the research community 
(Fig. 2). Users can now complete an online form that can 
be continuously updated on the Interagency Modeling 
and Analysis Group wiki site [9]. We plan to formalize 
the process, which may include evolving the Committee 
into an independent body that will oversee the perpetu-
ation of the rules and guidelines beyond the Interagency 
Modeling and Analysis group and the Multiscale Mod-
eling Consortium initiative.
Few things serve to educate and exemplify these Ten 
Rules for credible practice of modeling and simulation 
better than examples of the modeling and simulation 
community following and communicating these credible 
practices. As part of our effort to promote modeling and 
simulation credible practices, the Committee has created 
an open repository of models and simulations that epito-
mize application of each of the Ten Rules. Updated yearly, 
this repository [79], hosts modeling and simulation links, 
descriptions, and summaries of example credibility 
descriptions, as well as links to common standards, mod-
eling and simulation repositories, and suggested report-
ing formats for modeling and simulation credibility. Since 
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its formation, the Committee has followed an agile, con-
tinuous process to understand modeling and simulation 
activities in light of their impact on perceived credibility 
of the practice. A diverse group of stakeholders have con-
tributed to this understanding through discussions, posi-
tion statements, surveys, and so on, and continue to do 
so. The Committee’s efforts have been inclusive, essen-
tially open to anyone with the dedication to contribute. 
The transparency of our activities provides insight into 
our collective thought process through openly accessi-
ble meeting minutes, discussion summaries, survey data, 
presentations, and implementation examples. The Com-
mittee routinely solicits and incorporates feedback from 
the Interagency Modeling and Analysis group and the 
Multiscale Modeling Consortium [9], and grantee activi-
ties continue to integrate the Ten Rules as part of their 
modeling and simulation practices via federal funding 
programs. This portrayal is intended to demonstrate that 
the Committee practices what it preaches, supporting 
FAIR principles and mirroring the philosophy of the Ten 
Rules. The Committee welcomes suggestions, example 
submissions, and comments on credible practice activi-
ties to share with the broader modeling and simulation 
healthcare community, with the hopes of fostering more 
in-depth discussion and commonplace adoption of these 
guidelines in the credible practice of modeling and simu-
lation in healthcare.
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